{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:12:12Z","timestamp":1707523932830},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,29]]},"DOI":"10.7759\/cureus.47899","type":"journal-article","created":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T13:55:05Z","timestamp":1698587705000},"source":"Crossref","is-referenced-by-count":0,"title":["Inhibition of Oral Fibrinogenesis Through Transforming Growth Factor-Beta\/SMAD2\/3 Signalling Inhibition Using Mangosteen Pericarp Extract"],"prefix":"10.7759","author":[{"given":"Jency Evanjelin","family":"P","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umamaheswari","family":"TN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elumalai","family":"Perumal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1054\/bjom.1999.0062","article-title":"Clinical and functional staging of oral submucous fibrosis","volume":"38","author":"Haider SM","year":"2000","unstructured":"Haider SM, Merchant AT, Fikree FF, Rahbar MH. Clinical and functional staging of oral submucous fibrosis. Br J Oral Maxillofac Surg. 2000, 38:12-15. 10.1054\/bjom.1999.0062","journal-title":"Br J Oral Maxillofac Surg"},{"key":"ref2","article-title":"Oral submucous fibrosis: etiology, pathogenesis, and future research","volume":"72","author":"Rajendran R","year":"1994","unstructured":"Rajendran R. Oral submucous fibrosis: etiology, pathogenesis, and future research. Bull World Health Organ. 1994, 72:985-996.","journal-title":"Bull World Health Organ"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6631856","article-title":"Research achievements of oral submucous fibrosis: progress and prospect","volume":"2021","author":"Xu H","year":"2021","unstructured":"Xu H, Lyu FY, Song JY, et al.. Research achievements of oral submucous fibrosis: progress and prospect. Biomed Res Int. 2021, 2021:6631856. 10.1155\/2021\/6631856","journal-title":"Biomed Res Int"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/jicd.12473","article-title":"Immunoexpression of alpha smooth muscle actin correlates with serum transforming growth factor-\u03b21 levels in oral submucous fibrosis","volume":"10","author":"Singh I","year":"2019","unstructured":"Singh I, Juneja S, Tandon A, Jain A, Shetty DC, Sethi A. Immunoexpression of alpha smooth muscle actin correlates with serum transforming growth factor-\u03b21 levels in oral submucous fibrosis. J Investig Clin Dent. 2019, 10:e12473. 10.1111\/jicd.12473","journal-title":"J Investig Clin Dent"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0714.2002.00117.x","article-title":"High incidence of autoantibodies in Taiwanese patients with oral submucous fibrosis","volume":"31","author":"Chiang CP","year":"2002","unstructured":"Chiang CP, Hsieh RP, Chen TH, et al.. High incidence of autoantibodies in Taiwanese patients with oral submucous fibrosis. J Oral Pathol Med. 2002, 31:402-409. 10.1034\/j.1600-0714.2002.00117.x","journal-title":"J Oral Pathol Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.4103\/njms.NJMS_32_17","article-title":"Oral submucous fibrosis: newer proposed classification with critical updates in pathogenesis and management strategies","volume":"8","author":"Passi D","year":"2017","unstructured":"Passi D, Bhanot P, Kacker D, Chahal D, Atri M, Panwar Y. Oral submucous fibrosis: newer proposed classification with critical updates in pathogenesis and management strategies. Natl J Maxillofac Surg. 2017, 8:89-94. 10.4103\/njms.NJMS_32_17","journal-title":"Natl J Maxillofac Surg"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/jop.12581","article-title":"Oral submucous fibrosis: an update on current theories of pathogenesis","volume":"46","author":"Arakeri G","year":"2017","unstructured":"Arakeri G, Rai KK, Hunasgi S, Merkx MA, Gao S, Brennan PA. Oral submucous fibrosis: an update on current theories of pathogenesis. J Oral Pathol Med. 2017, 46:406-412. 10.1111\/jop.12581","journal-title":"J Oral Pathol Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0714.1994.tb00083.x","article-title":"Distribution of procollagen type III, collagen type VI and tenascin in oral submucous fibrosis (OSF)","volume":"23","author":"Reichart PA","year":"1994","unstructured":"Reichart PA, van Wyk CW, Becker J, Schuppan D. Distribution of procollagen type III, collagen type VI and tenascin in oral submucous fibrosis (OSF). J Oral Pathol Med. 1994, 23:394-398. 10.1111\/j.1600-0714.1994.tb00083.x","journal-title":"J Oral Pathol Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1006\/cyto.1997.0342","article-title":"Immunolocalization of cytokines and growth factors in oral submucous fibrosis","volume":"10","author":"Haque MF","year":"1998","unstructured":"Haque MF, Harris M, Meghji S, Barrett AW. Immunolocalization of cytokines and growth factors in oral submucous fibrosis. Cytokine. 1998, 10:713-719. 10.1006\/cyto.1997.0342","journal-title":"Cytokine"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2111401118","article-title":"Local versus systemic control of bone and skeletal muscle mass by components of the transforming growth factor-\u03b2 signaling pathway","volume":"118","author":"Liu Y","year":"2021","unstructured":"Liu Y, Lehar A, Rydzik R, et al.. Local versus systemic control of bone and skeletal muscle mass by components of the transforming growth factor-\u03b2 signaling pathway. Proc Natl Acad Sci U S A. 2021, 118:e2111401118. 10.1073\/pnas.2111401118","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/molecules22020275","article-title":"Anti-bacterial and anti-fungal activity of xanthones obtained via semi-synthetic modification of \u03b1-mangostin from Garcinia mangostana","volume":"22","author":"Narasimhan S","year":"2017","unstructured":"Narasimhan S, Maheshwaran S, Abu-Yousef IA, Majdalawieh AF, Rethavathi J, Das PE, Poltronieri P. Anti-bacterial and anti-fungal activity of xanthones obtained via semi-synthetic modification of \u03b1-mangostin from Garcinia mangostana. Molecules. 2017, 22:275. 10.3390\/molecules22020275","journal-title":"Molecules"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2008.07.024","article-title":"Medicinal properties of mangosteen (Garcinia mangostana)","volume":"46","author":"Pedraza-Chaverri J","year":"2008","unstructured":"Pedraza-Chaverri J, C\u00e1rdenas-Rodr\u00edguez N, Orozco-Ibarra M, P\u00e9rez-Rojas JM. Medicinal properties of mangosteen (Garcinia mangostana). Food Chem Toxicol. 2008, 46:3227-3239. 10.1016\/j.fct.2008.07.024","journal-title":"Food Chem Toxicol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S241093","article-title":"Quercetin inhibits epithelial-to-mesenchymal transition (EMT) process and promotes apoptosis in prostate cancer via downregulating lncRNA MALAT1","volume":"12","author":"Lu X","year":"2020","unstructured":"Lu X, Chen D, Yang F, Xing N. Quercetin inhibits epithelial-to-mesenchymal transition (EMT) process and promotes apoptosis in prostate cancer via downregulating lncRNA MALAT1. Cancer Manag Res. 2020, 12:1741-1750. 10.2147\/CMAR.S241093","journal-title":"Cancer Manag Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2008.73","article-title":"Analyzing real-time PCR data by the comparative C(T) method","volume":"3","author":"Schmittgen TD","year":"2008","unstructured":"Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008, 3:1101-1108. 10.1038\/nprot.2008.73","journal-title":"Nat Protoc"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2021.04.012","article-title":"Honokiol inhibits arecoline-induced oral fibrogenesis through transforming growth factor-\u03b2\/Smad2\/3 signaling inhibition","volume":"120","author":"Chen PY","year":"2021","unstructured":"Chen PY, Ho DC, Liao YW, et al.. Honokiol inhibits arecoline-induced oral fibrogenesis through transforming growth factor-\u03b2\/Smad2\/3 signaling inhibition. J Formos Med Assoc. 2021, 120:1988-1993. 10.1016\/j.jfma.2021.04.012","journal-title":"J Formos Med Assoc"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.19070\/2377-8075-21000777","article-title":"Clinical practice guidelines for management of oral submucous fibrosis","volume":"8","author":"Dhanvanth M","year":"2021","unstructured":"Dhanvanth M, Uma Maheswari TN. Clinical practice guidelines for management of oral submucous fibrosis. Int J Dentistry Oral Sci. 2021, 8:3791-3794. 10.19070\/2377-8075-21000777","journal-title":"Int J Dentistry Oral Sci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2022.105801","article-title":"Targeting head and neck cancer epigenetics with CRISPR-dCas9: an emerging therapeutic approach","volume":"127","author":"Elumalai P","year":"2022","unstructured":"Elumalai P, Ezhilarasan D, Lakshmi T. Targeting head and neck cancer epigenetics with CRISPR-dCas9: an emerging therapeutic approach. Oral Oncol. 2022, 127:105801. 10.1016\/j.oraloncology.2022.105801","journal-title":"Oral Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2022.106113","article-title":"Restoring the anti-tumor property of PTEN: a promising oral cancer treatment","volume":"134","author":"Shree Harini K","year":"2022","unstructured":"Shree Harini K, Ezhilarasan D, Elumalai P. Restoring the anti-tumor property of PTEN: a promising oral cancer treatment. Oral Oncol. 2022, 134:106113. 10.1016\/j.oraloncology.2022.106113","journal-title":"Oral Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jff.2020.104200","article-title":"Garcinia mangostana peel extracts exhibit hepatoprotective activity against thioacetamide-induced liver cirrhosis in rats","volume":"74","author":"Abood WN","year":"2020","unstructured":"Abood WN, Bradosty SW, Khudaboddin Shaikh F, et al.. Garcinia mangostana peel extracts exhibit hepatoprotective activity against thioacetamide-induced liver cirrhosis in rats. J Funct Foods. 2020, 74:104200. 10.1016\/j.jff.2020.104200","journal-title":"J Funct Foods"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2147\/JEP.S233111","article-title":"Alpha-mangostin improves cardiac hypertrophy and fibrosis and associated biochemical parameters in high-fat\/high-glucose diet and low-dose streptozotocin injection-induced type 2 diabetic rats","volume":"12","author":"Soetikno V","year":"2020","unstructured":"Soetikno V, Murwantara A, Andini P, Charlie F, Lazarus G, Louisa M, Arozal W. Alpha-mangostin improves cardiac hypertrophy and fibrosis and associated biochemical parameters in high-fat\/high-glucose diet and low-dose streptozotocin injection-induced type 2 diabetic rats. J Exp Pharmacol. 2020, 12:27-38. 10.2147\/JEP.S233111","journal-title":"J Exp Pharmacol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.22159\/ijap.2019.v11s1.16144","article-title":"The effect of alpha-mangostin on transforming growth factor beta 1 (tgf-\u03b21) and matrix metalloproteinase-3 expression in tgf-\u03b2-induced hepatic stellate cells","volume":"11","author":"Adenina S","year":"2019","unstructured":"Adenina S, Rahmaniah R, Yuyuntia Y, Soetikno V, Louisa M. The effect of alpha-mangostin on transforming growth factor beta 1 (tgf-\u03b21) and matrix metalloproteinase-3 expression in tgf-\u03b2-induced hepatic stellate cells. Int J Appl Pharm. 2019, 11:177-180. 10.22159\/ijap.2019.v11s1.16144","journal-title":"Int J Appl Pharm"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2022.106100","article-title":"Emerging applications of CRISPR\/Cas9 gene editing technology in reversing drug resistance in oral squamous cell carcinoma","volume":"134","author":"Elumalai P","year":"2022","unstructured":"Elumalai P, Ezhilarasan D. Emerging applications of CRISPR\/Cas9 gene editing technology in reversing drug resistance in oral squamous cell carcinoma. Oral Oncol. 2022, 134:106100. 10.1016\/j.oraloncology.2022.106100","journal-title":"Oral Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/187504-inhibition-of-oral-fibrinogenesis-through-transforming-growth-factor-betasmad23-signalling-inhibition-using-mangosteen-pericarp-extract","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:54:37Z","timestamp":1707508477000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/187504-inhibition-of-oral-fibrinogenesis-through-transforming-growth-factor-betasmad23-signalling-inhibition-using-mangosteen-pericarp-extract"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,29]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.47899","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,29]]}}}